In this study, we show that hypoxia in tumours induced by anti-VEGF antibody treatment induces GM-CSF expression, which causes MDSC recruitment into tumour sites, leading to immunosuppression and tumour progression, and in turn, resistance to anti-VEGF therapy. This evidence concerns the gene VEGFA and neoplasm.